These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 14714252

  • 1. Captopril reduces portal pressure effectively in portal hypertensive patients with low portal venous velocity.
    Baik SK, Park DH, Kim MY, Choi YJ, Kim HS, Lee DK, Kwon SO, Kim YJ, Park JW, Chang SJ.
    J Gastroenterol; 2003; 38(12):1150-4. PubMed ID: 14714252
    [Abstract] [Full Text] [Related]

  • 2. Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis.
    Feu F, Bordas JM, Luca A, García-Pagán JC, Escorsell A, Bosch J, Rodés J.
    Hepatology; 1993 Nov; 18(5):1082-9. PubMed ID: 8225212
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis.
    Albillos A, Bañares R, González M, Ripoll C, Gonzalez R, Catalina MV, Molinero LM.
    Am J Gastroenterol; 2007 May; 102(5):1116-26. PubMed ID: 17391317
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis.
    Turnes J, Garcia-Pagan JC, Abraldes JG, Hernandez-Guerra M, Dell'Era A, Bosch J.
    Am J Gastroenterol; 2006 Mar; 101(3):506-12. PubMed ID: 16542287
    [Abstract] [Full Text] [Related]

  • 7. Octreotide enhances portal pressure reduction induced by propranolol in cirrhosis: a randomized, controlled trial.
    Vorobioff JD, Ferretti SE, Zangroniz P, Gamen M, Picabea E, Bessone FO, Reggiardo V, Diez AR, Tanno M, Cuesta C, Tanno HE.
    Am J Gastroenterol; 2007 Oct; 102(10):2206-13. PubMed ID: 17608776
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension.
    La Mura V, Abraldes JG, Raffa S, Retto O, Berzigotti A, García-Pagán JC, Bosch J.
    J Hepatol; 2009 Aug; 51(2):279-87. PubMed ID: 19501930
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis.
    Schneider AW, Kalk JF, Klein CP.
    Hepatology; 1999 Feb; 29(2):334-9. PubMed ID: 9918907
    [Abstract] [Full Text] [Related]

  • 13. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension.
    Escorsell A, Bordas JM, Castañeda B, Llach J, García-Pagán JC, Rodés J, Bosch J.
    Hepatology; 2000 May; 31(5):1061-7. PubMed ID: 10796880
    [Abstract] [Full Text] [Related]

  • 14. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.
    Manolakopoulos S, Triantos C, Theodoropoulos J, Vlachogiannakos J, Kougioumtzan A, Papatheodoridis G, Tzourmakliotis D, Karamanolis D, Burroughs AK, Archimandritis A, Raptis S, Avgerinos A.
    J Hepatol; 2009 Sep; 51(3):468-74. PubMed ID: 19616339
    [Abstract] [Full Text] [Related]

  • 15. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG, Albillos A, Bañares R, Turnes J, González R, García-Pagán JC, Bosch J.
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [Abstract] [Full Text] [Related]

  • 16. Hemodynamic effects of a combination of prazosin and terlipressin in patients with viral cirrhosis.
    Lee WC, Lin HC, Yang YY, Hou MC, Lee FY, Chang FY, Lee SD.
    Am J Gastroenterol; 2001 Apr; 96(4):1210-6. PubMed ID: 11316172
    [Abstract] [Full Text] [Related]

  • 17. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.
    Spahr L, Giostra E, Frossard JL, Morard I, Mentha G, Hadengue A.
    Am J Gastroenterol; 2007 Jul; 102(7):1397-405. PubMed ID: 17488248
    [Abstract] [Full Text] [Related]

  • 18. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
    Bañares R, Moitinho E, Piqueras B, Casado M, García-Pagán JC, de Diego A, Bosch J.
    Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
    [Abstract] [Full Text] [Related]

  • 19. Clinical usefulness of the angiotensin II receptor antagonist losartan in patients with portal hypertensive gastropathy.
    Wagatsuma Y, Naritaka Y, Shimakawa T, Kanako H, Keiichiro I, Shunichi S, Konno S, Katsube T, Ogawa K.
    Hepatogastroenterology; 2006 Jul; 53(68):171-4. PubMed ID: 16608017
    [Abstract] [Full Text] [Related]

  • 20. NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study.
    Berzigotti A, Bellot P, De Gottardi A, Garcia-Pagan JC, Gagnon C, Spénard J, Bosch J.
    Am J Gastroenterol; 2010 May; 105(5):1094-101. PubMed ID: 19920806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.